Provider/Grant Support
This activity is supported in part by an independent education grant from Johnson and Johnson and Varian Health Systems.
Credits Available
- Physicians — maximum of 2.0 AMA PRA Category 1 Credits™
- Nurses — 2.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of Interventional oncologists, interventional radiologists, medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, palliative care, pathologists, advanced practice providers, pharmacists, nurse navigators and other healthcare professionals who play a major role in the treatment of patients with NSCLC.
Program Overview
This course provides an overview of contemporary strategies in the diagnosis and management of non–small cell lung cancer (NSCLC) with an emphasis on multidisciplinary collaboration. It highlights the importance of presenting early-stage cases at tumor board to ensure that surgical, medical oncology, radiation oncology, pathology, pulmonology, and interventional radiology perspectives are incorporated into individualized treatment planning. Learners explore the growing role of liquid biopsy for detecting circulating tumor DNA, the application of next-generation sequencing to identify actionable mutations, and the expanding use of minimally invasive ablation techniques as lung-sparing options for selected patients. The course also reviews appropriate timelines for post-treatment imaging after neoadjuvant therapy and examines how biomarkers such as PD-L1 expression inform immunotherapy decisions. Collectively, the module underscores how integrated diagnostics, molecular testing, and procedural innovations shape modern NSCLC care.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest innovations in ablative treatments, such as radiofrequency ablation (RFA) and cryoablation, as well as radiation therapies, and their use in treating early-stage or inoperable NSCLC.
- Discuss cutting-edge surgical options, including minimally invasive approaches like video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries, and their impact on patient recovery and outcomes.
- Discuss strategies for improving communication and collaboration among medical oncologists, thoracic surgeons, pulmonologists, and radiation oncologists to deliver comprehensive, patient-centered care for lung cancer patients.
Faculty
Dr. Scott Genshaft
Dr. Scott Genshaft is an interventional radiologist and the Director of Community Outpatient Interventional Radiology at UCLA Health in Los Angeles, California.
Dr. Venkatesh Krishnasamy
Dr. Venkatesh Krishnasamy is an interventional radiologist at University of Alabama at Birmingham.
Dr. Alan Lee
Dr. Alan Lee is a radiation oncologist and Clinical Assistant Professor at UCLA Health in Los Angeles, California.
Dr. Scott Oh
Dr. Scott Oh is an interventional pulmonologist and Professor of Medicine at the University of Southern California in Los Angeles, California.
Dr. Robert Suh
Dr. Rob Suh is a chest radiologist and interventional radiologist with UCLA in California.
Dr. Scott Atay
Dr. Scott Atay is a thoracic surgeon at Keck School of Medicine of the University of Southern California.
Dr. Karen Reckamp
Dr. Karen Reckamp is a Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai Medical Center in Los Angeles, California.
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
ACCME designates this enduring activity for a maximum of 2.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Conflict of Interest
Dr. Alan Lee
- Non-Mutual Funds Stock Ownership: Telix Pharmaceuticals
Dr. Scott Oh
- Employee: Intuitive Surgical
Dr. Karen Reckamp has no financial disclosures.
Dr. Venkatesh Krishnasamy
- Consultant/Advisory Board: Varian Medical, Instylla, Delcath, Cook, Merit, Boston Scientific
Dr. Scott Genshaft
- Consultant/Advisory Board: Boston Scientific, GE Healthcare, Intuitive Surgical, Stryker, Varian Medical
Dr. Rob Suh
- Speaker (Non-CME): Neuwave Medical; Galvanize Therapeutics
- Consultant/Advisory Board: Boston Scientific, Varian Medical
Dr. Scott Atay has no financial disclosures.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
Postgraduate Institute of Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]